New potential therapeutic agents for myeloma are on the horizon

the ONA take:

Recent therapeutic progress has improved outcomes for patients with myeloma; however, the complex biology of this disease continues to challenge treatment. “Myeloma is considered a treatable cancer, but not necessarily a curable cancer,” reported Sundar Jagannath, MD, of Mount Sinai Medical Center in New York, New York, at the Chemotherapy Foundation Symposium. Developing a targeted therapy is hindered by the lack of a clear molecular target for the disease, and every patient’s disease becomes refractory to all current therapeutic agents. Jagannath described the theoretical optimal targeted therapy as one that increases the rate of complete response and progression-free survival (PFS); it should be well tolerated in older patients (most patients with myeloma are older than 70 years) as well as patients with renal impairment or cytopenia; it should demonstrate value across different lines of therapy; and it should maintain its effectiveness regardless of genetic profile or mutations. In this article Jagannath reviews several drugs that may become part of the therapeutic arsenal for myeloma, including the monoclonal antibodies elotuzumab and daratumumab, the proteasome inhibitor ixazomib, and the histone deaetylase (HDAC) inhibitor panobinostat.

New potential therapeutic agents for myeloma are on the horizon
New potential therapeutic agents for myeloma are on the horizon
NEW YORK -- Recent improvement in myeloma outcomes will likely continue into the foreseeable future, as new classes of agents become available, including immunotherapy, according to a review of therapeutic progress. However, considerable room for improvement remains, particularly in terms of boosting long-term survival, said Sundar Jagannath, MD, of Mount Sinai Medical Center in New York City, at the Chemotherapy Foundation Symposium.
READ FULL ARTICLE From Medical Page Today
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs